90 results
8-K
EX-99.1
FATE
Fate Therapeutics Inc
9 May 24
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
4:02pm
conditioning, extended hospitalization, risk of secondary malignancies, and limited access. In addition, while we continue with the preclinical assessment … " translational assessment using a sample of the patient’s blood obtained prior to administration of conditioning chemotherapy,
FT819 induced rapid
8-K
EX-99.1
FATE
Fate Therapeutics Inc
9 May 24
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
9:01am
-of-kind” translational assessment using a sample of the patient’s blood obtained prior to administration of conditioning chemotherapy, FT819 induced rapid
8-K
EX-99.1
g27 0vdm8b
26 Feb 24
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
4:03pm
8-K
EX-99.1
aqehq0l
3 May 23
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
4:06pm
8-K
EX-99.1
k24wvg s5bj94yhs41h
3 Aug 22
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
4:03pm
8-K
EX-99.1
m32o vau9ofjvg67a
28 Feb 22
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
4:06pm
8-K
EX-99.1
nlipr 6t30qo
14 Dec 21
Other Events
5:28pm